Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 7M | 14.1% |
| Gross Profit | 5.1M | 16% |
| Cost of Revenue | 1.9M | 9.5% |
| Operating expense | 14M | 54.2% |
| Net Income | -6.7M | 72% |
| EBITDA | -5.8M | 75.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 214M | 2.6% |
| Total Liabilities | 11M | 1% |
| Total Equity | 203M | 2.8% |
| Shares Outstanding | 980M | 0% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -4.8M | 28.6% |
| Cash from investing | 6.5M | 73.4% |
EPS
Financial Highlights for Zomedica in Q3 '24
Zomedica reported a revenue of 7M, which is a 14.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 5.1M, marking a 16% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1.9M, a 9.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 14M, showing a -54.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -6.7M, showing a 72% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -5.8M, showing a 75.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Zomedica with growth in revenue, gross profit, and net income.
